论文部分内容阅读
目的:探讨化疗联合过继免疫细胞(CIK细胞、DC细胞)治疗晚期非小细胞肺癌的临床疗效。方法:按照随机数字表法将我院收治的86例晚期非小细胞肺癌患者分为对照组与试验组(43例/组)。对照组应用化疗方案治疗;试验组于化疗的基础上联合应用过继免疫细胞治疗。统计两组患者临床疗效、不良反应发生率情况。结果:试验组患者临床治疗总有效率明显优于对照组(P<0.05);且试验组治疗期间不良反应发生率亦明显低于对照组(P<0.05)。结论:临床中治疗晚期非小细胞肺癌疾病,于化疗基础上联合应用过继免疫细胞疗法,其临床疗效显著,且用药安全,有极高的临床应用价值。
Objective: To investigate the clinical efficacy of chemotherapy combined with adoptive immune cells (CIK cells, DC cells) in the treatment of advanced non-small cell lung cancer. Methods: 86 cases of advanced non-small cell lung cancer admitted to our hospital were divided into control group and experimental group (43 cases / group) according to random number table method. The control group was treated with chemotherapy regimen; the experimental group was treated with adoptive immune cells in combination with chemotherapy. Statistics of two groups of patients with clinical efficacy, the incidence of adverse reactions. Results: The total effective rate of clinical trial in trial group was significantly higher than that in control group (P <0.05). The incidence of adverse reactions in trial group was also significantly lower than that in control group (P <0.05). Conclusion: Clinical treatment of advanced non-small cell lung cancer, combined with chemotherapy based on the application of adoptive immune cell therapy, the clinical efficacy was significant, and medication safety, a very high clinical value.